Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Total Non-Current Liabilities (2023 - 2025)

Zenas BioPharma has reported Total Non-Current Liabilities over the past 3 years, most recently at $78.8 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $78.8 million for Q4 2025, up 36068.35% from a year ago — trailing twelve months through Dec 2025 was $78.8 million (up 36068.35% YoY), and the annual figure for FY2025 was $78.8 million, up 36068.35%.
  • Total Non-Current Liabilities for Q4 2025 was $78.8 million at Zenas BioPharma, up from $73.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ZBIO hit a ceiling of $78.8 million in Q4 2025 and a floor of $218000.0 in Q4 2024.
  • Median Total Non-Current Liabilities over the past 3 years was $48.3 million (2023), compared with a mean of $43.9 million.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 99.07% in 2024 and later soared 36068.35% in 2025.
  • Zenas BioPharma's Total Non-Current Liabilities stood at $23.5 million in 2023, then crashed by 99.07% to $218000.0 in 2024, then soared by 36068.35% to $78.8 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $78.8 million (Q4 2025), $73.2 million (Q3 2025), and $218000.0 (Q4 2024) per Business Quant data.